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Transitioning from multi-phase to single-phase
microfluidics for long-term culture and treatment
of multicellular spheroids†
Kay S. McMillan,a Marie Boydb and Michele Zagnoni*a
When compared to methodologies based on low adhesion or hanging drop plates, droplet microfluidics
offers several advantages for the formation and culture of multicellular spheroids, such as the potential for
higher throughput screening and the use of reduced cell numbers, whilst providing increased stability for
plate handling. However, a drawback of the technology is its characteristic compartmentalisation which
limits the nutrients available to cells within an emulsion and poses challenges to the exchange of the en-
capsulated solution, often resulting in short-term cell culture and/or viability issues. The aim of this study
was to develop a multi-purpose microfluidic platform that combines the high-throughput characteristics
of multi-phase flows with that of ease of perfusion typical of single-phase microfluidics. We developed a
versatile system to upscale the formation and long-term culture of multicellular spheroids for testing anti-
cancer treatments, creating an array of fluidically addressable, compact spheroids that could be cultured in
either medium or within a gel scaffold. The work provides proof-of-concept results for using this system
to test both chemo- and radio-therapeutic protocols using in vitro 3D cancer models.
1. Introduction
Cancer continues to be a major problem worldwide, with a
prediction that the number of new cases will reach over 20
million by 2030.1 Although there has been an increase in the
number of anticancer chemotherapies developed over the
past decade, their success rate has been poor, with less than
10% of anticancer drugs progressing to clinical trials.2,3 Fur-
thermore, improvements are required in radiation therapy for
certain types of cancer, such as glioblastoma, where treatment
failure remains high.4 To this end, more physiologically rele-
vant preclinical cancer models than those based on cancer
cell monolayers can lead to develop more efficacious thera-
pies. Multicellular tumour spheroids are in vitro 3D cancer
models which can mimic the heterogeneous cell composition
and the microenvironmental features seen in in vivo tu-
mours,3,5 representing an ideal candidate model during drug
discovery.6,7 However, standard methods for the formation
and study of multicellular tumour spheroids (e.g. spinner
flask, hanging drop and low adhesion plates) are generally la-
bour intensive and low-throughput.3 Therefore, the develop-
ment of robust and automatable microfluidic technologies
based on spheroid models has the potential to facilitate the
adaptation of existing screening protocols and increase the
data throughput when testing anticancer therapies.
In recent years, droplet microfluidics techniques8 have
been increasingly used for the formation and culture of
multicellular spheroids and organoids.9–16 These methods in-
volve the encapsulation of cells or cell aggregates within an
aqueous (or gel) droplet in an oil phase, with the aqueous–oil
interface being biocompatible and presenting non-adhering
characteristics.17,18 In comparison to established methods,
such as those based on spinner flasks or hanging drops, cell
encapsulation in aqueous/gel-in-oil droplets prevents expo-
sure of cells to shear stress19 and provides a stable environment
that is insensitive to mechanical perturbation, respectively.6
Arguably, the greatest advantage that droplet microfluidics
can offer is that of significantly increasing the throughput of
information, where assays can be developed allowing the for-
mation of up to 1000 spheroids per device.16 However, a
drawback of emulsion-based methods for cell culture is
compartmentalisation, where each droplet acts as an environ-
mentally isolated experiment, thus limiting the volume of nu-
trients available to the cells and concentrating build-up of
waste products,11,12,20,21 both of which have a detrimental ef-
fect on cell viability over time. Other limitations when work-
ing with emulsion techniques include the inability to directly
perfuse the dispersed phase content and to prevent the parti-
tion of encapsulated substances (i.e. lipophilic drugs) into
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the oil phase. Therefore, a microfluidic approach capable of
overcoming these limitations would aid long-term cell culture
after their encapsulation in emulsions and the development
of multi-step anticancer treatment tests (e.g. repeated injec-
tion of drugs at specific time points after spheroid formation
over weeks of culture).
It has been previously shown that biocompatible fluoro-
surfactants can be used for the formation and culture of
spheroids within single and double emulsions.6,9 This is
obtained due to the polyethylglycol (PEG) head of the surfac-
tant used, which creates a non-adherent water/oil interface,
resulting in cancer cells aggregating within the emulsion to
form compact spheroids. Additionally, we have shown that
the ability to regulate the microenvironmental factors during
spheroid culture within emulsions is a key aspect to ensure
their viability and to control cell quiescence,6 elements that
affect spheroid response to radiotherapeutic investigation.
Therefore, a microfluidic approach that integrates the
compartmentalisation and high-throughput features of drop-
let microfluidics with the ease of perfusion of single-phase
laminar flows would offer a universal microfluidic platform
for screening multicellular spheroids.
The fluorosurfactants used in the previous studies are
known to produce stable and long lasting emulsions when
water or salt solutions were used as the dispersed phases.18
However, it has been reported that molecules, such as bovine
albumin serum (BSA), can destabilise the emulsion interface
and increase their chance of coalescence.18 This aspect could
explain the need for microfluidic designs that keep emul-
sions from contacting each other when encapsulating cells.22
Therefore, an approach that exploits induced interface insta-
bility to create controlled emulsion coalescence could provide
a solution to the compartmentalization issues during cell cul-
ture with droplet microfluidics.
In this study, we present a microfluidic system that allows
both chemotherapy and radiotherapy protocols to be investi-
gated in an array of multicellular spheroids over weeks of cul-
ture. The procedure is based on the controllable coalescence
of multiple emulsion interfaces after the initial spheroid for-
mation, enabling injection of fresh media and drugs to be de-
livered at desired time points. The system was used to dem-
onstrate culture of spheroids under various experimental
conditions (e.g. with and without the use of 3D matrix scaf-
folds). Using a human glioma cell line (UVW),6 we have
characterised the growth rate of spheroids, their response to
X-ray irradiation and to anticancer compounds, showing the
wide range of applicability of the proposed microfluidic sys-
tem to develop powerful screening assays.
2. Experimental
2.1. Device preparation
Microfluidic devices were fabricated using standard soft- and
photo-lithography techniques as previously described.6
Briefly, master templates were produced using SU8 photore-
sist (3000 series, MicroChem, US) onto a silicon wafer follow-
ing the manufacturer's protocol, achieving a final resist thick-
ness of 200 μm. The resist was exposed through a photomask
(JD Photo-Tools, UK) to UV light and was developed in Micro-
Posit EC solvent (Rohm and Haas, US). Polydimethylsiloxane
(PDMS) was poured onto the silicon master at a 10 : 1 ratio of
base to curing agent, degassed in a vacuum desiccator cham-
ber and cured at 80 °C for at least 2 hours. To prevent PDMS
adhesion to the silicon master, the wafer's surface was
silanised by vapour deposition of 1H,1H,2H,2H-perfluorooctyl-
trichlorosilane (Sigma Aldrich, UK) for 1 hour. The PDMS de-
vices were then peeled from the mould, cut to the desired
size, and holes were punched using G21 needles to obtain in-
let and outlet ports. PDMS devices were then cleaned and ir-
reversibly bonded to glass microscope slides using oxygen
plasma. Bonded devices were then treated with undiluted
Aquapel (PPG Industries) to obtain fluorophilic microchannel
surfaces.
2.2. Cell culture and spheroid formation
A human glioblastoma cell line (UVW) developed in house
was utilised.23 UVW cells were maintained in an atmosphere
of 5% CO2 and incubated at 37 °C, in minimum essential
medium (MEM), containing 10% (v/v) of foetal calf serum
(FCS), L-glutamine (200 mmol l−1), penicillin/streptomycin
(100 U ml−1) and Fungizone (2 μg ml−1). Medium and addi-
tional supplements were purchased from Invitrogen, UK.
2.3. Microfluidic protocols
FC-40 (3 M) fluorinated oil with 2% wt block copolymer
fluorosurfactants (designed by the Weitz Group at Harvard
and supplied by RAN Biotechnologies, catalogue# 008-
FluoroSurfactant, Beverly, MA, USA) was used as the continu-
ous phase in all experiments. To better visualise the
destabilisation of emulsion interfaces, an aqueous phase
containing 100 μM of calcein (Sigma Aldrich, UK) in either
water or medium was used. For spheroid experiments, a cell
suspension at a concentration of 3 × 106 cells per ml in me-
dium was used. Polytetrafluoroethylene (PTFE) tubing (Cole
Parmer) was used to connect syringes to the inlet ports of the
microfluidic device and syringe pumps (AL-1000, World Preci-
sion Instruments, Hertfordshire) were used to inject the
phases. Two device structures were used: one to quantify
emulsion coalescence in a large chamber (Fig. S1 in ESI†)24
and another to carry out spheroid experiments (Fig. 2), based
on a modified version of a previously reported design.25–27
Medium in oil (M/O) droplets (with or without cells) were
formed at a T-junction and then stored within the device. For
spheroid culture, medium was refreshed every 2 days and de-
vices were incubated after seeding at an atmosphere of 5%
CO2 and at 37 °C. For spheroid withdrawal medium was dis-
pensed through the outlet to displace spheroids from their
traps.
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2.4. Alginate bead preparation
Sodium alginate (Sigma Aldrich, UK) was dissolved into me-
dium at a concentration of 2% (w/v), heated to 50 °C for 2
hours and stored at 4 °C prior to use. The sodium alginate
solution was filtered through a 0.2 μm filter to remove any
particulate after storing it in a fridge. A cell suspension of 3 ×
106 cells per ml in the sodium alginate mixture was used as a
dispersed phase. To carry out gelation of the alginate drop-
lets, a 4% (w/v) solution of calcium chloride in medium was
filtered through a 0.2 μm filter to remove any particulate and
perfused through the device. After droplet gelation, the cal-
cium chloride solution was replaced by medium which was
subsequently refreshed every 2 days to replenish nutrients to
the spheroids.
2.5. Viability staining of spheroids
Spheroids were stained for cell viability using fluorescein
diacetate (FDA) and propidium iodide (PI) (Sigma Aldrich,
UK). The staining solution, containing 20 μg ml−1 of PI and
8 μg ml−1 of FDA, was loaded into a syringe and perfused
through the device for approximately 20 minutes. Spheroids
were incubated in the staining solution for approximately 15
minutes then washed with phosphate buffer saline (PBS) be-
fore imaging.
2.6. Radiation treatment of spheroids
Spheroids were allowed to form and cultured in M/O droplets
as previously described6 and irradiated with a single dose of
8 Gy using a PXI X-Rad 225C X-irradiator, set to a dose rate
equating to 2.2 Gy per min (RPS Services, Surrey, UK). Subse-
quently, both control and irradiated spheroids were cultured
as previously described and their size monitored for up to 12
days.
2.7. Dosimetry measurements
For calibration purposes, a UNIDOS® E universal dosimeter
with a CC04 ionisation chamber (PTW, Germany) was used to
measure the amount of radiation that was absorbed by a
glass slide and a PDMS slab (∼5 mm thick) respectively, as
well as by a PDMS/glass microfluidic device.
2.8. Drug treatment of spheroids
Cisplatin (Sigma Aldrich, UK) was dissolved in 0.9% sodium
chloride solution to make a stock solution of 1 mM. Doxoru-
bicin (Sigma Aldrich, UK) was dissolved in deionised water to
make a stock solution of 5 mM. For treatment, the cisplatin
stock solution was diluted to 50 μM with complete medium
and the doxorubicin stock solution was diluted to 4 μM with
complete medium. Spheroids were allowed to form and cul-
tured in M/O droplets as previously described and perfused
for 30 minutes with the desired anticancer compound. After
24 hours, the incubated drug solution was washed from the
device and replaced by medium to replenish nutrient and cre-
ate a favourable growth condition for the spheroids. Subsequently,
both control and cisplatin-treated or doxorubicin-treated
spheroids were cultured for up to 12 or 14 days to assess
treatment efficacy.
2.9. Spheroid growth measurement
Spheroid growth was monitored over time by measuring the
increase of their diameter after day 1 of culture (when com-
pact spheroids were obtained) with brightfield microscopy,
using a Zeiss inverted microscope (Axiovert A1) and a
Labview controlled Dalsa Genie CMOS HM1024 camera.
Spheroid dimensions were estimated using ImageJ by mea-
suring the longest and shortest diameters (D1 and D2, re-
spectively) to calculate their average diameter. The Mann
Whitney test was used to evaluate the statistical difference
between experiments (significant difference between groups
obtained for p value ≤ 0.05).
3. Results and discussion
The device geometry and protocols developed in this work
rely on the combination of a microfluidic passive channel
network that enables M/O droplets, encapsulating a cell sus-
pension, to be trapped within an array of sites and the con-
trolled rupture of the emulsion interfaces once compact
spheroids were formed within the array. Experiments were
firstly conducted to determine the causes of emulsion coales-
cence. Subsequently, using the same device structure, micro-
fluidic protocols were established for spheroid long-term cul-
ture using both complete medium (matrix-free condition)
and calcium alginate gels (scaffold-supported condition)
whilst performing periodic medium exchange. Finally, the
system was validated for carrying out in vitro radiotherapeutic
and chemotherapeutic assays using spheroids.
3.1. Factors influencing emulsion coalescence
The fluorosurfactants used in this study are known to pro-
duce emulsions with robust,18 long-lasting28 and biocompati-
ble oil/water interfaces, thus enabling favourable conditions
for the culture of cells, organisms20 and multicellular spher-
oids.6 However, when emulsions containing cell medium
were incubated in close contact with each other and in static
conditions, we observed undesired and increasing emulsion
coalescence over a period of time ranging from tens of mi-
nutes to a few hours, a condition that never occurred when
encapsulating deionised water solutions. Therefore, we inves-
tigated the factors that compromised emulsion stability by
testing emulsion coalescence when using various aqueous
phases that are typically required for the culture of mamma-
lian cells. In addition, these experiments were also carried
out investigating the effects on coalescence due to tempera-
ture variation and mechanical shocks, practical factors in-
volved in the long-term culture of cells and when handling
microfluidic devices from cell incubators to microscope
stages or plate readers. The aqueous phases included
deionised water, PBS, MEM without additives, MEM with
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individual additives and the complete cell medium used for
cell culture of UVW cells (i.e. containing growth factors, anti-
fungals, antibiotics, etc.).
To carry out this investigation, aqueous droplets in oil
were formed and stored within a microfluidic chamber
(∼1300 aqueous droplets per chamber) that allowed for emul-
sion interfaces to be in close contact with each other (Fig. S1
in ESI†). The number of non-coalesced emulsions in the
chamber upon initial loading was compared to the number
of non-coalesced emulsions after 30 minutes under three
conditions: while stationary, within an incubator at 37 °C, or
after a ‘mild’ mechanical shock produced by placing the de-
vice on a microscope stage holder. This analysis provided the
resulting percentage of emulsion coalescence for each case
(Fig. 1) which was calculated as follows:
(1)
where NDroplets (t = 0) equals the number of droplets at the
start of the experiment and NDroplets (t = x) equals the number
of droplets after a certain period of time. As expected, and in
agreement with the literature, when using deionised water,
PBS or MEM without supplements (1–3 in Fig. 1A), no coales-
cence was observed except for the case of incubating droplets
at 37 °C. In contrast, when medium was used in combination
with any of the supplements (4–9 in Fig. 1A), droplet coales-
cence increased significantly even when the device was kept
stationary and at ambient temperature. In these conditions, a
mild physical shock (i.e. produced by placing the device on a
microscope holder) was observed to increase the chance of
coalescence by twice as much with respect to its stationary
state. As expected, storing the device inside a cell incubator
showed a progressive increase in coalescence from deionised
water to PBS and from MEM to full medium. Above all, addi-
tives typically used for cell culture, such as FBS, Fungizone
and penicillin/streptomycin, strongly enhanced the instability
of the emulsion interface in comparison to minimum essen-
tial medium alone. As previously described for emulsions
made using the same fluorosurfactants, additive molecules
within the encapsulated phase, such as bovine serum albu-
min (BSA),18 can interact with the surfactant monolayer at
the emulsion interface, resulting in the displacement of the
surfactants and leading to emulsion coalescence. Relevant to
our study, one of the components of FBS is albumin and it
can be assumed that this molecule, in combination with
other supplements, could be responsible for the increased
emulsion instability observed. However, due to the complex-
ity and variety of additives in full cell medium, further inves-
tigation needs to be carried out to identify other potential
molecular causes related to coalescence.
3.2. Device operation principle: from emulsions to single
phase microfluidics
The analysis presented in the previous section highlighted
how molecules typically present in cell culture medium can
facilitate emulsion coalescence. Here, we exploit this aspect
to our advantage. We present a two steps procedure whereby
droplet microfluidics protocols were first used to encapsulate
cells within emulsions and allowed their transformation into
multicellular spheroids in compartmentalized growth sites in
parallel. Subsequently, within the same microfluidic struc-
ture, perfusion of complete medium replaced the continuous
oil phase and resulted in the controlled rupture of the emul-
sion interfaces, thus enabling subsequent medium exchange,
guaranteeing long term culture and the delivery of chemicals
to the pre-formed spheroids at the desired time points.
Fig. 1 Effect of the aqueous phase composition on coalescence of
contacting emulsions. (A) Bar chart showing the percentage of
coalesced emulsions for different aqueous phases in varied
experimental conditions. An initial number of approximately 1000
emulsions (NDroplet (t = 0) = 1000 in eqn (1)) were considered for each
case (1 trial per case is shown). After droplet formation, emulsions
were stored in a microfluidic chamber: (white) devices were kept
stationary on a microscope stage for 30 min; (grey) devices were
manually placed on a microscope stage producing a mild mechanical
shock; (black) devices were transferred from a cell incubator at 37 °C
to the microscope stage after 30 min. The %Coalescence value was
calculated using eqn (1). Representative images of coalescence of
droplet in oil-surfactants within a microfluidic chamber using
deionised water (B) and complete medium (C) before and after placing
the device on a microscope. 1 is deionised water; 2 is PBS; 3 is MEM; 4
is MEM with FBS; 5 is MEM with Fungizone; 6 is MEM with Pen/Strep; 7
is MEM with FBS and Pen/Strep; 8 is MEM with FBS and Fungizone and
9 is MEM with all of the supplements for UVW cell culture. The scale
bar is 350 μm.
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For this, a microfluidic design was developed based on
the work by Boukellal et al.25 and Vanapalli et al.26,27,29 The
microfluidic channel network consisted of a serial array of
traps allowing for the sequential storage of M/O droplets
(Fig. 2A). When a plug approached an empty trapping site, it
followed the path with the smallest fluidic resistance and en-
tered a round chamber within which its surface tension en-
ergy was minimised, with the emulsion changing its shape
from an oblong plug to a round droplet (Fig. 2B 1–2). A sub-
sequent plug would bypass the trapped droplet without coa-
lescence and slot in the next available empty round chamber
(Fig. 2B 3–4) until all the trapping sites were occupied (Movie
S1†). At this point, only the continuous phase was flown
through the device channels to remove any non-trapped
droplet and exited the device both from the array and the by-
pass channel outlets (3A and 4A in Fig. 1). In this condition,
tubing was detached from the device with the emulsions
remaining ‘locked’ into the round chambers, enabling spher-
oid incubation for as long as required.
To induce rupture of the emulsion interfaces, a solution
of full medium (containing molecules that could destabilise
the emulsion interface as previously discussed) was injected
into the device after 24 hours. This formed a long plug that
pushed the oil left in the microchannel towards the outlets
without displacing the trapped droplets (Fig. 2C 1–4). Subse-
quently, coalescence of the trapped droplets with the long
plug was observed within minutes (Fig. 2C 5–8 and Movie
S2†). As a control experiment, when water was used as the
aqueous phase, no coalescence of the plug with the trapped
droplets occurred (not shown).
In contrast to previous reports,27,30 by following this proto-
col, emulsion coalescence occurred without the need to alter
the surfactant concentration in the oil phase and with a rela-
tively simple procedure that did not require the use of active
PDMS valves or electrocoalescence strategies.31,32 Whilst for
organisms such as C. Elegans low concentration of surfac-
tants (0.001% w/v) are typically tolerated,30 when using mam-
malian cell suspensions the biocompatibility guaranteed by
the PEG-fluorocarbon surfactants (2% w/v) is essential for
long term culture and to provide a non-adherent interface
which is required to induce cellular aggregation.6
3.3. Formation and culture of multicellular spheroids
We have previously demonstrated how emulsion technologies
can be exploited to control the level of proliferation and qui-
escence of multicellular spheroids.6 However, the major limi-
tation to scaling up the techniques developed was the need
for accessing and exchanging the emulsion inner phase, proce-
dures that were carried out manually. In this work, following
the protocol detailed in section 3.2, we demonstrate proof-of-
concept of in vitro chemotherapy and radiotherapy assays
within a single, scalable and automatable microfluidic plat-
form, enabling direct access to the cultured spheroid micro-
environment to be obtained via microfluidic perfusion.
Here, spheroids were formed in plugs containing a sus-
pension of glioma cells and these were trapped within the
storage array. In brief, a cell suspension incubated in a rest-
ing droplet sedimented at the bottom of the droplet on the
biocompatible PEG layer at the medium/oil interface. Due
to the non-adherent nature of the PEG head of the fluoro-
surfactants, cells tended to aggregate into a compact spher-
oid structure.6 Droplet trapping efficiency was 100%, with
each droplet encapsulating between 60 and 160 cells for
the cell concentration used (Fig. 3). This variation in cell
number within droplets is due to the fact that particle
Fig. 2 Microfluidic protocol for emulsion production, storage and
interface disruption. (A) Layout of the microfluidic device: aqueous
phase-in-oil plugs are generated at a T-junction; 1A is the oil phase in-
let; 2A is the aqueous phase inlet; 3A is the bypass channel outlet; 4A
is the outlet and 5A is the chamber array. (B) Schematic diagram show-
ing the plug trapping mechanism: a plug approaches an empty storing
chamber and remains trapped within it (1 and 2); subsequent plugs by-
pass the occupied round chamber and enter in the next available trap
(3 and 4) (Movie S1†). (C) Time-lapse of brightfield & fluorescent im-
ages (1 to 5) and fluorescent images (6 to 8) of a long plug containing
medium with calcein interacting with emulsion interfaces and eventu-
ally leading to interface rupture. Images 1 to 4 show the long plug en-
tering the serial array and coming into contact with the droplets in the
traps without initial coalescence. Images 5 to 8 show the sequential
rupture of the interface between the stored droplets and plug. Calcein
is then observed to diffuse inside the stored droplet following emul-
sion interface rupture (Movie S2†). The scale bar is 400 μm.
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encapsulation in emulsions follows a Poisson distribution.33
Additionally, we sometimes observed a fluctuation in the flow
due to cell clustering that influenced the number of cell en-
capsulated per M/O droplet. After trapping, droplets
containing cells were incubated for approximately 24 hours
at 5% CO2 and at 37 °C, allowing for the formation of com-
pact cell aggregates, as previously described.6 During this
step, the use of PEG-fluorocarbon surfactants was essential to
guarantee a non-adherent substrate, thus inducing cell aggre-
gation. Although a slight shrinkage of the M/O droplets was
observed over this time (which can be compensated for by in-
creasing the humidity level during incubation), due to me-
dium evaporation, the emulsions did not displace from the
traps and no detrimental effects were produced to spheroid
viability.
After 1 day of culture, compact spheroids were obtained,
ranging from 40 to 150 μm in diameter depending on the ini-
tial cell number within the M/O droplet (Movie S3†). Overall,
spheroid size variation within a device can be advantageous
when performing screening assays as, due to the proportion
of quiescent to proliferative cells in a spheroid, different re-
sponses to treatment can be observed.6 After 24 hours, a long
plug of medium was created in the device to coalesce the
interface of the emulsions containing spheroids, with spher-
oids being occasionally displaced from the trapping sites if
their size was <40 μm. Subsequently, the device was perfused
every 2 days with fresh medium for 30 minutes (at 0.5 μL
min−1) and the growth of spheroids was monitored by
brightfield microscopy. As shown in Fig. 3, spheroids
remained compact and did not adhere to the device substrate
for a period of 17 days (max time point tested in this work).
Therefore, this suggests that a non-adherent PEG-layer is
maintained in the trapping sites even after interface rupture
and oil removal. Spheroids grew over time, suggesting that
the medium perfusion protocol was adequate to supply cells
with the required nutrition for proliferation, as well as to re-
move waste products. The viability of spheroids was con-
firmed by carrying out live/dead staining with FDA and PI,
with no dead cells observed after 17 days of culture for the
control experiments. These findings demonstrate that spher-
oid long-term culture can be robustly achieved using this
approach.
For the cell line used, only viability staining was
conducted as the UVW glioma cell line does not change cell
characteristics according to treatment. However, if other cell
types were used and specific biomarkers were released, any
appropriate immunoassay could be carried out and/or analy-
sis of the retrieved medium (10–15 μl) could be conducted.
Additionally, we also developed a procedure to retrieve the
spheroids from the microfluidic device after formation. This
was obtained by injecting medium from the outlet (4A in
Fig. 2) which displaced the spheroids slowly from their trap-
ping sites (Fig. S2†), leading them into the main serpentine.
Spheroids ultimately exited the device from the auxiliary out-
let (3A in Fig. 2) for off-chip post-processing if required (e.g.
spheroid sectioning or flow cytometry analysis). The viability
of spheroids extracted from the device was confirmed by car-
rying out live/dead staining with FDA and PI from control
Fig. 3 Formation and culture of multicellular glioma spheroids. (A) Stitched brightfield images of cell suspensions encapsulated in aqueous
droplets trapped within the array on day 0. For clarity of image, 30 trapping sites are shown out of the 48 available. (B) Same field of view after
interface rupture on day 1 showing formation of spheroids. (C) Representative time-lapse images of spheroid formation and growth over 17 days,
at which the spheroids were stained for viability with FDA and PI. The scale bar for (A) and (B) is 400 μm and for (C) is 200 μm.
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experiments, showing that the procedure had no detrimental
effect to the integrity of the multicellular structure.
Other multiphase approaches in the literature have in-
cluded the use of microfluidic double emulsions for spheroid
culture. However, a progressive reduction in cell viability of
cells was reported over time and was attributed to the fact
that growth factors were unable to diffuse across the oil
layer.9,34 In addition, with respect to the present study, the
formation of double emulsions adds complexity to the drop-
let formation process (mainly due to the need for hydro-
philic/hydrophobic patterns) with respect to single
emulsions.
Finally, the developed microfluidic protocols were tested
to provide proof-of-concept results for scalable chemo- and
radio-therapeutic assays.
3.4. Spheroid response to irradiation and drug treatment
Prior to cell-based experiments, dosimetry measurements
were carried out to determine if any radiation was absorbed
by the device materials, resulting in approximately 8% of the
radiation intensity to be absorbed by the PDMS layer (∼5
mm thick).
Spheroids were treated with a single dose of 8 Gy X-ray ir-
radiation on day 7 of culture and their size monitored in
comparison to a control experiment (unirradiated spheroids).
A value of 8 Gy irradiation was chosen as previous experi-
ments had shown that UVW glioma spheroids are highly
radioresistant.6 A significant reduction (p < 0.001) in spher-
oid diameter was observed in comparison to the control ex-
periment on day 12 of culture (Fig. 4A), which was confirmed
by live/dead staining (Fig. 4B).
Alternatively, following the protocol described in section
3.3, spheroids were formed and a solution of either cisplatin
or doxorubicin was perfused through the device on day 7 of
culture. The spheroids were then left to incubate in the pres-
ence of the drug for 24 hours. Subsequently, medium was
perfused through the device to wash out the drug solution. A
significant reduction (p < 0.01) in spheroid diameter was ob-
served in comparison to the control (no drug) 7 days after
treatment for cisplatin and 5 days after treatment for doxoru-
bicin (Fig. 5A). On day 14 for cisplatin and day 12 for doxoru-
bicin, a significant amount of cells had disaggregated from
the spheroids (Fig. 5B and C) and their viability assessed
using live dead staining. As for irradiated spheroids, if their
size was considerably reduced, medium exchange could lead
to spheroid displacement from their site of culture. Our pre-
vious study6 has shown that radiation treatment and relapse
mechanisms are dependent on the number of quiescent and
proliferative cells in a spheroid. This microfluidic protocol
could be used to scale-up the investigation of such effects
using combination therapy and implementing protocols
based on multiple steps of drug delivery. The device structure
used in our experiments hosted 48 spheroids (Fig. 2),
allowing for statistical information to be extracted from a sin-
gle device per treatment and for differently sized spheroids.
However, the channel design is scalable and the protocol de-
veloped can be easily adapted according to the size of the
substrate used and the readout instrumentation. In the fu-
ture, in order to increase the number of drug concentrations
tested simultaneously, multiple devices with N spheroids
could be connected in parallel by linking an inlet from each
device to an outlet of a microfluidic gradient generator. This
would enable N repeats for several drug concentrations to be
performed on the same substrate, achieving similar out-
comes as to those obtained in 384 well plates,35 with no re-
quirements for expensive robotic dispensing instrumenta-
tion, as well as allowing for gel scaffolds to be used for cell
culture.
3.5. Spheroid formation in alginate beads
Recurrently, alginate beads or microcapsules have been used
in spheroid-based microfluidic studies,12,15,18 rather than
aqueous droplets, due to the ease of perfusing solutions
through the gel porous structure and with the idea of provid-
ing a 3D scaffold environment as a beneficial support for cell
culture.11,36 Therefore, the developed microfluidic protocol
was also tested to determine its suitability for carrying out
spheroid culture within alginate beads.
Fig. 4 Radiation treatment of glioma spheroids. (A) The growth curve
shows the average spheroid diameter (μm) over days of culture in the
microfluidics for both control (untreated spheroids – continuous line)
and radiation experiments (spheroid treated with 8 Gy on day 7 – as
indicated by the arrow – dashed line) with the error bars representing
the standard error of the mean (n = 23). (B) Representative time-lapse
images of the radiation experiment with live/dead stain on day 12. The
scale bar is 200 μm. *** represents a p value ≤ 0.001. The reduction in
spheroid size in combination with viability staining is used as an indica-
tor of spheroid health and efficacy of the treatment.
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To achieve alginate gelation, divalent cations such as cal-
cium ions are required to cross link with the carboxylic
groups of the G block monomers which make up part of the
alginate polysacharide.37 Alginate droplets containing cells
were formed and used as described in section 3.3. Once the
droplets were trapped within the array in the round cham-
bers, a calcium chloride solution was flown through the
channels to promote alginate gelation by diffusion through
the emulsion interface (Fig. 6C–E). Occasionally, a reduction
in the alginate bead size was observed over time. This behav-
iour has been previously reported and is thought to be due to
the release of Ca2+ into the medium.36
In contrast to spheroids formed within aqueous droplets
(Fig. 6A and B), the cells encapsulated in alginate beads ag-
gregated at a slower rate (3–4 days passed before spheroid
formation), initially forming less smooth and compact spher-
oids, with some cells remaining separated from the main
spheroid body throughout the culture. Similar characteristics
Fig. 5 Drug treatment of spheroids. The growth curve (A) shows the
average spheroid diameter over 12 to 14 days for control (untreated
spheroids – continuous line), cisplatin (spheroids treated with 50 μM –
as – dashed black line) and doxorubicin (spheroids treated with 4 μM –
dashed-dot grey line) experiments. The arrow indicates the day of
treatment for both drugs (day 7) applied for 24 hours. The error bars
represent the standard error of the mean (n = 18). Representative
time-lapse images of spheroids (B) treated with cisplatin and (C)
treated with doxorubicin with FDA and PI staining performed on day
14 or 12 respectively. The scale bar is 200 μm. ** represents a p value
of ≤ 0.01. The reduction in spheroid size in combination with viability
staining is used as an indicator of spheroid health and the efficacy of
the treatment.
Fig. 6 Formation of spheroids within alginate beads. Brightfield
images showing cells encapsulated in medium with alginate (A and C)
on day 0 and after interface rupture using medium with (B) and
without (D) calcium chloride. White arrows in (D) points to the alginate
interface formed after perfusion of calcium chloride. (E) Representative
time-lapse images of spheroids formed within alginate beads and
stained with FDA and PI on day 5. The scale bars for A–D is 400 μm
and for E is 200 μm.
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for cell aggregation and spheroid formation have been previ-
ously shown.10,11 Furthermore, within alginate droplets
which were not exposed to calcium chloride, the cells aggre-
gated much faster, with times comparable to those when
using aqueous droplets. This reinforces the idea that cell ag-
gregation is delayed when cells are embedded in a more vis-
cous gel environment.
4. Conclusion
In this work, we have developed a new microfluidic protocol
that harnesses the advantages of the compartmentalisation
properties of droplet microfluidics to create multicellular
spheroids and those of controllable perfusion typical of
single-phase microfluidics. The proposed methodology is
scalable and enables the transition from multi-phase to
single-phase flows, thus allowing long-term cell culture, drug
perfusion and is amenable to cell culture applications that re-
quire the use of gel scaffolds. We have obtained proof-of-
concept data demonstrating spheroid response to radiation
and chemotherapy agents and have shown that the protocol
can be used with both aqueous and alginate beads (scaffold-
supported cell culture), allowing for user-defined culture con-
ditions to be implemented. In the future, this system has the
potential to be further scaled-up for drug concentration tests
and used for in vitro radiotherapy and chemotherapeutic
combination treatments to identify potential radiosensitising
agents for radioresistant tumours.
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